Benin on track to join elite who’s who of who certified pharmaceutical regulators

Between 6 and 9 July 2026, the Bénin Medicines and Health Products Agency (ABMed) underwent a meticulous evaluation by a panel of World Health Organization (WHO) specialists. This intensive assessment highlighted remarkable progress, placing the country on the verge of securing the coveted Maturity Level 3 certification. A milestone that would crown nearly ten years of sweeping structural reforms in the health sector.

An exhaustive review of Bénin’s pharmaceutical watchdog

Over four days, Bénin’s health system came under the microscope during a landmark regulatory audit. A team of eight international WHO experts meticulously reviewed the legal framework, operational activities, and regulatory practices of the ABMed. No stone was left unturned—from drug market authorization to post-market surveillance, pharmacovigilance, and clinical trials. The mission aimed to measure how closely Bénin’s processes align with the world’s most stringent international standards.

The findings, unveiled on 9 July 2026 in Cotonou, painted an encouraging picture. The assessment confirmed significant strides, validating that Bénin is crossing a critical threshold toward securing its health product supply chain.

What the WHO’s Maturity Level 3 really means

In WHO’s regulatory classification system, Maturity Level 3 (ML3) signifies a country with a stable, fully functional, and integrated pharmaceutical regulatory system. Achieving this status means national authorities can exert robust, effective control over all medicines circulating within the country.

For Bénin’s citizens, this certification is a promise of access to safe, high-quality, and efficacious health products. Beyond public health benefits, the status serves as a powerful economic and geopolitical asset. It bolsters international trust, encourages local drug manufacturing, and eases exports to neighboring markets. Most importantly, it sends a strong signal in the fight against counterfeit medicines, reinforcing consumer confidence.

A decade of reform reaches its climax

The evaluation results were shared in a public session attended by Health Minister Professor Benjamin Hounkpatin, who expressed deep satisfaction with the findings. In his address, he commended the ABMed team for their dedication and the transformative progress achieved.

For Bénin’s leadership, this pending certification is no accident—it is the culmination of bold, systemic reforms launched in 2017. By transforming the former pharmacy directorate into an autonomous agency (ABMed) and tightening legislation, the government laid the groundwork for this qualitative leap. Minister Hounkpatin reaffirmed the state’s unwavering commitment to supporting ABMed until the final certification is secured.

Bénin poised to become West Africa’s second francophone leader

The stakes of this evaluation extend far beyond national borders. If the final assessment confirms ML3, Bénin could become the second French-speaking country in West Africa to earn this global classification—just behind Sénégal.

This achievement would position Bénin as a future hub of excellence in health governance across the subregion. It also proves that with strong political will and sustained technical rigor, African nations can elevate their institutions to meet the highest global benchmarks.

The dawn of a new era in public health

The July 2026 WHO mission marks a historic turning point for public health in Bénin. If all indicators remain positive, ABMed teams must now maintain momentum and implement the experts’ final recommendations to officially upgrade their status. By nearing Maturity Level 3, Bénin demonstrates that patient safety and pharmaceutical sovereignty are no longer distant goals—but an unfolding reality.